期刊
LEUKEMIA
卷 19, 期 9, 页码 1648-1655出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.leu.2403884
关键词
antibody; Hodgkin's disease; CD30; combination; chemotherapy
SGN-30, a monoclonal antibody with activity against CD30(+) malignancies, is currently in phase II clinical evaluation for treatment of Hodgkin's disease (HD) and anaplastic large cell lymphoma. The mechanisms underlying SGN- 30's antitumor activity were investigated using cDNA array of L540 cells. SGN- 30 treatment activated NF- kappa B and modulation of several messages including the growth regulator p21(WAF1/CIP1) (p21) and cellular adhesion marker ICAM-1. p21 protein levels increased coincident with growth arrest and Annexin V/PI staining in treated HD cells. To determine if SGN-30-induced growth arrest would sensitize tumor cells to chemotherapeutics used against HD, L540cy and L428 cells were exposed to SGN-30 in combination with a panel of cytotoxic agents and resultant interactions quantified by the Combination Effects Method. Interactions between SGN-30 and all cytotoxic agents examined were additive or better. These in vitro data translated to increased efficacy of SGN-30 and bleomycin against L540cy tumor xenografts. In addition to direct cell killing, SGN-30 affects growth arrest and drug sensitization through growth regulating and proapoptotic machinery. Importantly, these data suggest that SGN-30 can enhance the efficacy of standard chemotherapies used to treat patients with CD30(+) malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据